Peter Lawson
Stock Analyst at Barclays
(2.09)
# 2,901
Out of 5,182 analysts
102
Total ratings
41.3%
Success rate
-5.63%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Lawson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ONC BeOne Medicines AG | Maintains: Overweight | $394 → $405 | $298.90 | +35.50% | 3 | Feb 27, 2026 | |
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $19 → $22 | $21.00 | +4.76% | 5 | Nov 4, 2025 | |
| INCY Incyte | Maintains: Overweight | $90 → $101 | $95.72 | +5.52% | 1 | Oct 29, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $40 | $29.48 | +35.69% | 1 | Sep 4, 2025 | |
| SDGR Schrödinger | Initiates: Overweight | $25 | $11.74 | +112.95% | 1 | Aug 14, 2025 | |
| REPL Replimune Group | Downgrades: Equal-Weight | $17 → $3 | $2.68 | +11.94% | 4 | Jul 23, 2025 | |
| EXEL Exelixis | Maintains: Equal-Weight | $29 → $40 | $44.65 | -10.41% | 6 | Jul 10, 2025 | |
| MGNX MacroGenics | Maintains: Overweight | $8 → $3 | $3.05 | -1.64% | 9 | May 14, 2025 | |
| FATE Fate Therapeutics | Maintains: Overweight | $10 → $2 | $1.31 | +52.67% | 4 | May 14, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | $5 → $10 | $8.66 | +15.47% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $3.43 | +16.62% | 7 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $22 → $6 | $13.10 | -54.20% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $52 | $28.56 | +82.07% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $11 | $9.07 | +21.28% | 1 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $16 | $10.29 | +55.49% | 8 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $4.77 | +214.47% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $14 | $24.95 | -43.89% | 7 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $3 | $1.73 | +73.41% | 5 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $3 | $1.31 | +129.01% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $4 | $1.53 | +161.44% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $60 | $131.67 | -54.43% | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $17 | $14.95 | +13.71% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $31 | $16.49 | +87.99% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $13 | $26.33 | -50.63% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $4.52 | +10.62% | 4 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3.5 | $4.29 | -18.41% | 4 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $355 → $365 | $128.52 | +184.00% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $46 | $24.43 | +88.29% | 2 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $450 | $86.74 | +418.82% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $17 → $45 | $2.89 | +1,457.09% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $16 → $45 | $50.99 | -11.75% | 2 | Jan 23, 2018 |
BeOne Medicines AG
Feb 27, 2026
Maintains: Overweight
Price Target: $394 → $405
Current: $298.90
Upside: +35.50%
Syndax Pharmaceuticals
Nov 4, 2025
Maintains: Overweight
Price Target: $19 → $22
Current: $21.00
Upside: +4.76%
Incyte
Oct 29, 2025
Maintains: Overweight
Price Target: $90 → $101
Current: $95.72
Upside: +5.52%
IDEAYA Biosciences
Sep 4, 2025
Initiates: Overweight
Price Target: $40
Current: $29.48
Upside: +35.69%
Schrödinger
Aug 14, 2025
Initiates: Overweight
Price Target: $25
Current: $11.74
Upside: +112.95%
Replimune Group
Jul 23, 2025
Downgrades: Equal-Weight
Price Target: $17 → $3
Current: $2.68
Upside: +11.94%
Exelixis
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $29 → $40
Current: $44.65
Upside: -10.41%
MacroGenics
May 14, 2025
Maintains: Overweight
Price Target: $8 → $3
Current: $3.05
Upside: -1.64%
Fate Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $10 → $2
Current: $1.31
Upside: +52.67%
Karyopharm Therapeutics
May 13, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $8.66
Upside: +15.47%
May 12, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $3.43
Upside: +16.62%
May 8, 2025
Maintains: Underweight
Price Target: $22 → $6
Current: $13.10
Upside: -54.20%
May 7, 2025
Maintains: Overweight
Price Target: $66 → $52
Current: $28.56
Upside: +82.07%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $11
Current: $9.07
Upside: +21.28%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $16
Current: $10.29
Upside: +55.49%
May 1, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $4.77
Upside: +214.47%
Apr 23, 2025
Maintains: Overweight
Price Target: $29 → $14
Current: $24.95
Upside: -43.89%
Apr 2, 2025
Maintains: Equal-Weight
Price Target: $11 → $3
Current: $1.73
Upside: +73.41%
Mar 7, 2025
Maintains: Overweight
Price Target: $14 → $3
Current: $1.31
Upside: +129.01%
Feb 27, 2025
Maintains: Overweight
Price Target: $9 → $4
Current: $1.53
Upside: +161.44%
Sep 27, 2024
Maintains: Overweight
Price Target: $54 → $60
Current: $131.67
Upside: -54.43%
Sep 10, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $14.95
Upside: +13.71%
Jul 15, 2024
Maintains: Overweight
Price Target: $20 → $31
Current: $16.49
Upside: +87.99%
May 24, 2024
Maintains: Overweight
Price Target: $18 → $13
Current: $26.33
Upside: -50.63%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $4.52
Upside: +10.62%
Jul 7, 2022
Maintains: Overweight
Price Target: $7 → $3.5
Current: $4.29
Upside: -18.41%
Aug 6, 2021
Maintains: Underweight
Price Target: $355 → $365
Current: $128.52
Upside: +184.00%
Oct 22, 2020
Upgrades: Overweight
Price Target: $46
Current: $24.43
Upside: +88.29%
Mar 4, 2020
Initiates: Overweight
Price Target: $450
Current: $86.74
Upside: +418.82%
Jan 23, 2018
Upgrades: Buy
Price Target: $17 → $45
Current: $2.89
Upside: +1,457.09%
Jan 23, 2018
Upgrades: Buy
Price Target: $16 → $45
Current: $50.99
Upside: -11.75%